HeyJaredBlood Adv
- Indexed articles, last 90 days
- 7
- Latest publication
- Sep 21, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Aug 7, 2026
Latest articles
Is Add-On Lenalidomide Effective in R/R Follicular Lymphoma? (opens the original)
Read excerpt
A phase 3 trial found that in older patients with relapsed/refractory (R/R) follicular lymphoma who had responded to salvage immunochemotherapy, adding lenalidomide to rituximab maintenance therapy did not significantly improve 2-year progression-free survival (PFS) compared with rituximab alone, although a numerical benefit was seen; the combination regimen was also associated with a higher incidence of adverse events. Notably, a subgroup analysis suggested a favorable benefit-risk balance with
Sequencing Method Flags AML Relapse Risk Around Transplant (opens the original)
Read excerpt
In patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML), high-sensitivity sequencing detected measurable residual disease (MRD) around allogeneic transplant, identified those at higher relapse risk, and showed that peritransplant MRD dynamics refined prognosis. "[The] findings underscore the limitations of single-marker MRD monitoring, as residual disease may persist in non-FLT3-ITD compartments. In this context, integration of multitarget
Chemo Drug Exposure Linked to CAR T-Cell Therapy Outcomes (opens the original)
Read excerpt
Patients with relapsed/refractory large B-cell lymphoma (LBCL) who achieved optimal fludarabine exposure during lymphodepletion chemotherapy had better progression-free survival after chimeric antigen receptor (CAR) T-cell therapy than those who did not achieve optimal exposure. "These findings highlight the importance of developing [pharmacokinetic] models in CAR T-cell patients and the need for accurate fludarabine concentration measurements to enable personalized dosing and optimize treatment
Many Patients With B-Cell Lymphoma Miss Second-Line Care (opens the original)
Read excerpt
Among patients with large B-cell lymphoma who initiated first-line therapy, 30% received second-line treatment, while 13% died within 12 months of starting first-line therapy without receiving second-line therapy. Only a minority of eligible, fit patients received chimeric antigen receptor T‑cell (CAR T) therapy. "[The] findings support ongoing clinical trials using novel therapies in the frontline setting and also emphasize the systemic issues that patients face in receiving curative, FDA-appro
Baseline PET-CT Scans May Flag High-Risk B-Cell Lymphoma (opens the original)
Read excerpt
A composite score derived from baseline FDG PET-CT imaging — combining total metabolic tumor volume (TMTV), maximal interlesion distance (Dmax), and median peripheral centroid distance (medPCD) — identified patients with primary mediastinal B-cell lymphoma (PMBL) at higher risk for death. "By integrating measures of tumor burden, spatial dissemination, and structural compactness, this model identifies a subgroup with inferior outcomes at diagnosis and may help inform future trial-based risk-adap
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.